About This Publication:

  • Print This Page
  • Text a Friend
  • Subscribe to an RSS Feed

Sample Content 

LOGIN


Sign up to stay informed--receive email notifications for this journal

Metabolic Syndrome
and Related Disorders

Editor-in-Chief: Ishwarlal (Kenny) Jialal, MD, PhD

ISSN: 1540-4196 • 10 Issues Annually • Online ISSN: 1557-8518

Current Volume: 12

Latest Impact Factor* is 1.916

*2013 Journal Citation Reports® published by Thomson Reuters, 2014

A dynamic new author services platform
to share, measure, and enhance the impact of your research
Complimentary one-year membership with submission to this journal

For Authors

  • Manuscript Submissions
  • NIH/HHMI Wellcome Trust Policies
  • Self-Archiving Policy
  • Open Access Policy
  • Manuscript Submissions

    Mary Ann Liebert, Inc. Submission Benefits Package

    Your submission to Metabolic Syndrome and Related Disorders provides you with robust tools and support to ensure maximum impact and readership for your work. By submitting your manuscript, you’ll receive:

    • Complimentary 12-month AuthorCite® membership
      Exclusively licensed by Mary Ann Liebert, Inc., AuthorCite® delivers a 360-degree view of your article from submission to publication to market impact. With an AuthorCite® membership, you’ll receive end-to-end manuscript submission tracking, a custom online microsite to promote you and your research, a professional suite of metrics and analytics to measure the impact of your article, 30-day OpenLink™ article sharing, and much more.
    • Rapid, rigorous peer-review and editorial attention
    • Immediate deposit to PubMed and other indexing services upon online publication
    • Exposure to thousands of thought-leaders in your field, maximizing readers, citations, and downloads
    • Fast Track online-ahead-of-print publication
    • Global availability in over 170 countries
    • Open Access publication options


    Submitting Your Manuscript

    Submitting your manuscript to Metabolic Syndrome and Related Disorders delivers a comprehensive benefits program that ensures high-quality review of your research and maximum impact for your work. This includes a one-year membership to AuthorCite™, a robust author services platform for increasing the visibility of your research, and includes the ability to freely share your article for 30 days. Metabolic Syndrome and Related Disorders carries a manuscript processing charge* of $49.00 USD upon submission of each new manuscript.

    Upon payment, you will be provided a Manuscript Submission Code, and will be prompted to enter this information when uploading your files to our peer-review system.  Please note:  Securing a token does not automatically create an account in our peer-review system. If you do not already have an account, you will be asked to create one before you can begin your submission.

    Submissions do not need to be completed at once. Submitting authors/agents may begin the submission process, save their work, and return to the site to complete the upload(s) at a later time. There is no limit on the number of times one can save their work and subsequently resume the submission. Doing so will not incur additional charges.

    Click here to submit your paper via our fast and user-friendly electronic submission system.


    Manuscript Revisions

    Processing charges and submission codes are NOT required for revisions to previously submitted papers. To upload a revision of a paper, the submitting author should log in to their Author Center at http://mc.manuscriptcentral.com/metabolic and click on “Revised Manuscripts in Draft.” The paper will appear in this area, and the submitting author will be able to upload revised files without paying any charges or entering a submission code.

    Please be sure to follow the Instructions for Authors below on Manuscript Preparation.  Authors whose submissions do not comply with the Instructions for Authors will have their papers un-submitted so that the file(s) may be adjusted accordingly. Directions regarding the necessary corrective actions will be provided in an email to the corresponding author at the time the paper is un-submitted. The submitting author/agent will then be provided the opportunity to re-upload the corrected file(s). If a paper is un-submitted, the paper will reside in the corresponding author’s “Author Center” as a draft, and the submitting author/agent will be able to make the necessary adjustments and re-upload the paper without incurring another manuscript processing charge.  

    *The manuscript processing charge is independent of editorial decision and is non-refundable.


    Statement of Purpose and Policy

    Metabolic Syndrome and Related Disorders provides an interdisciplinary forum to explore the pathophysiology, recognition, and treatment of the cluster of conditions associated with the evolving entity of metabolic syndrome. These include but are not limited to: central obesity, endothelial dysfunction, insulin resistance, dyslipidemia, glucose intolerance, type 2 diabetes, prothrombotic and pro-inflammatory states, hypertension, cardiovascular disease, and polycystic ovarian syndrome (PCOS). Manuscripts must not contain material that has been reported elsewhere.

    The Journal accepts both original contributions and Brief Reviews. Brief Reviews are usually solicited by the Editor or Associate Editors and should be on a relevant topic . Also Brief Reviews should be restricted to approximately 3500 words and 50 references.

     

    Preparation of Manuscript

    Type manuscripts double-spaced. Leave ample margins on sides, top and bottom.  Original manuscripts must be no longer than 3,000 words.
     

    The title page should include the authors’ names, academic degrees, and affiliations, the funding source (if appropriate), and a running title of up to 45 characters. Please indicate the name, complete mailing address, phone number, fax number, and e-mail address of the author to whom correspondence should be addressed. The second page should consist of an abstract of no more than 250 words. Abstracts of original articles should contain four paragraphs labeled as: Background, Methods, Results, and Conclusions. Abstracts of reviews should contain a single unstructured paragraph.

    Disclosure Statement

    Immediately following the Acknowledgments section, include a section entitled “Author Disclosure Statement.” In this portion of the paper, authors must disclose any commercial associations that might create a conflict of interest in connection with submitted manuscripts. This statement should include appropriate information for EACH author, thereby representing that competing financial interests of all authors have been appropriately disclosed according to the policy of the Journal. It is important that all conflicts of interest, whether they are actual or potential, be disclosed. This information will remain confidential while the paper is being reviewed and will not influence the editorial decision. Please see the Uniform Requirements for Manuscripts Submitted to Biomedical Journals at http://www.icmje.org/index.htlm#conflicts for further guidance. If no conflicts exist, the authors must state “No competing financial interests exist."

     

    Tables and Illustrations

    Each table with its title must appear on a separate page. Use Arabic numerals to number tables. Each table must stand alone, (i.e., contain all necessary information in the caption), be cited in text, and the table itself must be understood independently of the text. Details of experimental conditions should be included in the table footnotes. Information that appears in the text should not be repeated in the table, and tables should not contain data that can be given in the text in one or two sentences. Tables should be submitted as Microsoft word files, on separate pages from the text of the manuscript. All art should be submitted as TIFF or EPS files. Color, halftones, and grayscale should be at a minimum 300 dpi resolution. Line art should be at a minimum 900 dpi resolution. Color must be saved as CYMK. RGB color files will not work. PowerPoint or Excel files cannot be uploaded.  A list of figure legends should be supplied on a separate page at the end of the manuscript, double spaced. We encourage the submission of color figures. Please contact the publisher for color-printing costs.

    When naming your figure files, please label them with the first author's last name, followed by a period (.), and then list the figure number.  Ex:  Smith.0123. Fig1.  Label figures and tables inside the files in addition to naming the file with the figure or table number.  (ie:  When figures or table files are opened, the figure or table number should appear inside the file.)

    IMPORTANT


    Please upload individual files of all manuscript material — do NOT upload a single PDF file containing all text, figure, and table files of your paper.  Once all individual files are uploaded on to Manuscript Central, the system will automatically create a single PDF proof for you and the peer-review process.
     

    Abbreviations

    Abbreviations of journal titles should follow MEDLINE.

    References

    List references in consecutive numerical order (not alphabetically). All subsequent reference citations should be to the original number. Cite all references in the text or tables using superscript citations. Unpublished data and personal communications should not be listed as references.

    References to journal articles should include (1) authors (list first three, then et al.), (2) title, (3) journal name (as abbreviated in MEDLINE), (4) year, (5) volume number, and (6) inclusive page numbers, in that order.

    References to books should include: (1) authors, (2) chapter title (if any), (3) editor or author, (4) title of book, (5) city of publication, (6) publisher, and (7) year, in that order. Volume and edition numbers, specific pages, and name of translator should be included when appropriate. The author is responsible for the accuracy and completeness of the references and for their correct text citation.

    Examples:

    Journal

    7. Aljada A, Garg R, Ghanim, H, et al.  Nuclear factor-KappaB suppressive and inhibitor-KappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an anti-inflammatory action. J Clin Endocrinol Metab, 2001, 11:224-238.

    Book

    8. Vinson, G.P, Anderson, D.C, Evidence of Hypertension, Adrenal Glands, Vascular System, and Hypertension, Bristol, UK: Society for Endocrinology; 1997: 1-52.

    Permissions

    The author must obtain permission to reproduce figures, tables, and text from previously published material. Written permission must be obtained from the original copyright holder (generally the publisher, not the author or editor) of the journal or book concerned. An appropriate credit line should be included in the figure legend or table footnote, and full publication information should be included in the reference list. Written permission must be obtained from the author of any unpublished material and should accompany the manuscript.

    Reprints

    Reprints may be ordered by following the special instructions that will accompany page proofs, and should be ordered at the time the corresponding author returns the corrected page proofs to the Publisher. Reprints ordered after an issue is printed will be charged at a substantially higher rate.
     

    Publisher

    The Journal is published by Mary Ann Liebert, Inc., 140 Huguenot Street, New Rochelle, NY 10801-5215.  Telephone: (914) 740–2100; fax: (914) 740–2101.

  • NIH/HHMI Wellcome Trust Policies

    NIH Public Access Policy: In order to assist our authors who have NIH funding to comply with this policy, Mary Ann Liebert, Inc. publishers will deposit the final accepted paper (after copy-editing and proofreading) to PubMed Central (PMC) on behalf of the authors. Authors need not take any action. The manuscript's public access posting on PMC will occur 12 months after final publication. This service is provided free of charge. Please note that authors may not deposit manuscripts directly to PMC or other sites without permission from Mary Ann Liebert, Inc.

  • Self-Archiving Policy

    Mary Ann Liebert, Inc. is a "blue" publisher (as defined by Sherpa), as we allow self-archiving of post-print (ie final draft post-refereeing) or publisher's version/PDF.

    In assigning Mary Ann Liebert, Inc. copyright, the author retains the right to deposit such a 'post-print' on their own website, or on their institution's intranet, or within the Institutional Repository of their institution or company of employment, on the following condition, and with the following acknowledgement:

    This is a copy of an article published in the [JOURNAL TITLE] © [year of publication] [copyright Mary Ann Liebert, Inc.]; [JOURNAL TITLE] is available online at: http://online.liebertpub.com.

    Authors may also deposit this version on his/her funder's or funder's designated repository at the funder's request or as a result of a legal obligation, provided it is not made publicly available until 12 months after official publication.

  • Open Access Policy


    Choose Liebert Open Access Option!

    Ensure maximum visibility, discoverability, and impact for your article with our Liebert Open Access (OA) Option.

    Your investment guarantees:

    • Immediate, unrestricted global access in 170 countries
    • Maximum visibility for increased readers, citations, and downloads
    • Targeted email announcement highlighting your article to thousands of thought-leaders in your field
    • Rapid, rigorous peer-review and editorial attention
    • Fast Track online-ahead-of-print publication
    • Immediate upload to PubMed Central and other internationally recognized repositories*
    • Recognition on online Table of Contents with exclusive OA icon
    • Compliance with OA funding mandates with no embargo period
    • Savings on future OA article publication
    • Complimentary membership in AuthorCite®, the author services platform exclusively licensed by Mary Ann Liebert, Inc. that delivers the tools you need to maximize your professional impact.

    These valuable benefits are included with a one-time article processing charge (APC). APC charge varies based on journal, membership, and subsequent submissions.

    Contact openaccess@liebertpub.com for questions on article Open Access options. 

     *Please note that PubMedCentral, not the Publisher, has sole control over when the paper is made live on PMC.

     

    Is your Institution a member of the Liebert Author Advocacy Program?

    The Liebert Author Advocacy Program (LAAP) provides valuable membership benefits for OA publication to institutional and funding organizations, and supports global funding mandates.  Authors who are affiliated with LAAP member institutions receive all the valuable benefits of Liebert OA article publication, and more.

    For details, and to recommend institutional membership visit: www.authoradvocacy.com or contact laap@liebertpub.com 

     

     

     

Recommended Publications

You may be interested in the following publications:

    Diabetes Technology & Therapeutics

    Diabetes Technology & Therapeutics

    The only peer-reviewed journal providing healthcare professionals with information on new devices, drugs, drug delivery systems, and software for managing patients with diabetes.

    Childhood Obesity

    Childhood Obesity

    Explores effective, actionable strategies for weight management and obesity prevention in children and adolescents, with in-depth coverage on education, policy, health disparities and cultural sensitivities, and more.

Browse All Publications »